ATE370948T1 - Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen - Google Patents

Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen

Info

Publication number
ATE370948T1
ATE370948T1 AT03731906T AT03731906T ATE370948T1 AT E370948 T1 ATE370948 T1 AT E370948T1 AT 03731906 T AT03731906 T AT 03731906T AT 03731906 T AT03731906 T AT 03731906T AT E370948 T1 ATE370948 T1 AT E370948T1
Authority
AT
Austria
Prior art keywords
sup
inhibitors
hiv
compounds
aids
Prior art date
Application number
AT03731906T
Other languages
English (en)
Inventor
Melissa Egbertson
Jeffrey Melamed
H Marie Langford
Steven Young
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE370948T1 publication Critical patent/ATE370948T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
AT03731906T 2002-01-17 2003-01-13 Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen ATE370948T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34977502P 2002-01-17 2002-01-17

Publications (1)

Publication Number Publication Date
ATE370948T1 true ATE370948T1 (de) 2007-09-15

Family

ID=27613314

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03731906T ATE370948T1 (de) 2002-01-17 2003-01-13 Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen

Country Status (9)

Country Link
US (1) US7279487B2 (de)
EP (1) EP1467970B1 (de)
JP (1) JP4523281B2 (de)
AT (1) ATE370948T1 (de)
AU (1) AU2003216049B2 (de)
CA (1) CA2472372C (de)
DE (1) DE60315796T2 (de)
ES (1) ES2291642T3 (de)
WO (1) WO2003062204A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667307B2 (en) * 1997-12-19 2003-12-23 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
US7169932B2 (en) 2001-06-11 2007-01-30 Pfizer Inc. HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis
HN2002000136A (es) 2001-06-11 2003-07-31 Basf Ag Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis
US7094909B2 (en) 2001-06-11 2006-08-22 Agouron Pharmaceuticals, Inc. HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
ATE404537T1 (de) 2002-08-13 2008-08-15 Shionogi & Co Heterocyclische verbindungen mit hiv-integrase- hemmender wirkung
PA8586801A1 (es) 2002-10-31 2005-02-04 Pfizer Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
US7414045B2 (en) * 2002-12-27 2008-08-19 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Substituted pyrimido[1,2-a]azepines useful as HIV integrase inhibitors
JP2006516606A (ja) 2003-01-27 2006-07-06 ファイザー インコーポレイテッド Ｈｉｖインテグラーゼインヒビター、医薬組成物、およびそれらの使用
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
CA2542047A1 (en) 2003-10-20 2005-05-12 Merck & Co., Inc. Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors
KR20070002006A (ko) 2004-02-11 2007-01-04 스미스클라인 비참 코포레이션 Ｈｉｖ 인테그라제 억제제
JP2007528394A (ja) * 2004-03-09 2007-10-11 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬
US20070161639A1 (en) 2004-03-09 2007-07-12 Philip Jones Hiv integrase inhibitors
AU2005220767A1 (en) * 2004-03-09 2005-09-22 Merck & Co., Inc. HIV integrase inhibitors
WO2005087767A1 (en) * 2004-03-09 2005-09-22 Merck & Co., Inc. Hiv integrase inhibitors
BRPI0510319A (pt) 2004-04-26 2007-10-16 Pfizer inibidores da enzima integrase de hiv
JP2007534738A (ja) 2004-04-26 2007-11-29 ファイザー・インク Ｈｉｖインテグラーゼ酵素の阻害剤
CN1964975B (zh) 2004-05-07 2011-11-30 默沙东公司 Hiv整合酶抑制剂
JP2008502741A (ja) 2004-06-09 2008-01-31 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬
AU2006228278C1 (en) * 2005-03-31 2011-06-23 Msd Italia S.R.L. HIV integrase inhibitors
EP3372281B1 (de) 2005-04-28 2021-07-07 VIIV Healthcare Company Polycyclisches carbamoylpyridonderivat mit hiv-integrase-hemmender aktivität
EP1881825B1 (de) * 2005-05-10 2013-07-24 Merck Sharp & Dohme Corp. Hiv-integrasehemmer
EP1909578A4 (de) * 2005-08-04 2010-07-14 Glaxosmithkline Llc Hiv-integrasehemmer
WO2007019101A2 (en) * 2005-08-04 2007-02-15 Smithkline Beecham Corporation Hiv integrase inhibitors
JP2009503082A (ja) * 2005-08-04 2009-01-29 スミスクライン ビーチャム コーポレーション Ｈｉｖインテグラーゼ阻害薬
AU2006299042B8 (en) 2005-10-04 2011-09-15 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa HIV integrase inhibitors
AU2006306355A1 (en) * 2005-10-27 2007-05-03 Merck & Co., Inc. HIV integrase inhibitors
WO2008004100A2 (en) 2006-07-05 2008-01-10 Pfizer Products Inc. Therapeutic compounds
PT2487165T (pt) 2006-07-07 2016-11-18 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
JP2009543867A (ja) * 2006-07-17 2009-12-10 メルク エンド カムパニー インコーポレーテッド 抗ｈｉｖ剤としての１−ヒドロキシナフチリジン化合物
US20100216834A1 (en) * 2006-10-18 2010-08-26 Isaacs Richard C A Hiv integrase inhibitors
ES2601820T3 (es) * 2007-02-23 2017-02-16 Gilead Sciences, Inc. Moduladores de propiedades terapéutica de las farmacocinéticas
WO2010006438A1 (en) 2008-07-17 2010-01-21 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
WO2010011818A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
EA201170537A1 (ru) * 2008-10-06 2011-12-30 Мерк Шарп Энд Домэ Корп. Ингибиторы вич-интегразы
SG181423A1 (en) 2009-12-23 2012-07-30 Univ Leuven Kath Novel antiviral compounds
US8283366B2 (en) 2010-01-22 2012-10-09 Ambrilia Biopharma, Inc. Derivatives of pyridoxine for inhibiting HIV integrase
WO2011120153A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
MX2013004169A (es) 2010-10-14 2013-06-05 Immunahr Ab 1, 2-dihidro-4-hidroxi-2-oxo-quinolina-3-carboxanilidas como activadores del receptor de hidrocarburo aromatico.
EP2640705A2 (de) 2010-11-15 2013-09-25 Katholieke Universiteit Leuven Neue antivirale verbindungen
CA2817896A1 (en) 2010-11-15 2012-05-24 Viiv Healthcare Uk Limited Inhibitors of hiv replication
WO2014099586A1 (en) 2012-12-17 2014-06-26 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
US9493479B2 (en) 2013-04-16 2016-11-15 Merck Sharp & Dohme Corp. Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors
ME02977B (de) 2013-05-17 2018-10-20 Merck Sharp & Dohme Kondensierte tricyclische heterocyclische verbindungen als hiv-integrase-hemmer
US9951079B2 (en) 2013-06-13 2018-04-24 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
EA030695B1 (ru) 2013-09-27 2018-09-28 Мерк Шарп И Доум Корп. Замещенные производные хинолизина, которые можно использовать как ингибиторы интегразы вич
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
WO2017087257A1 (en) 2015-11-17 2017-05-26 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors
US10544155B2 (en) 2015-12-15 2020-01-28 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors
WO2017113288A1 (en) 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
CN106008283B (zh) * 2016-06-29 2018-03-16 常州市阳光药业有限公司 牛磺酰胺盐酸盐的制备方法
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
RU2749043C2 (ru) 2016-12-02 2021-06-03 Мерк Шарп И Доум Корп. Трициклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич
EP3573984A4 (de) 2017-01-26 2020-07-29 Merck Sharp & Dohme Corp. Als hiv-integrase-inhibitoren nützliche, substituierte chinolizinderivate

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5268193A (en) * 1975-11-28 1977-06-06 Sumitomo Chem Co Ltd Synthesis of novel cephalosporin derivatives
FR2632639B1 (fr) 1988-06-09 1990-10-05 Sanofi Sa Derives d'amino-4 carboxy-3 naphtyridines, leur preparation et compositions pharmaceutiques qui les contiennent
SE9000624D0 (sv) * 1990-02-22 1990-02-22 Pharmacia Ab New use
WO1992004328A1 (en) * 1990-09-07 1992-03-19 Schering Corporation Antiviral compounds and antihypertensive compounds
IL101860A0 (en) 1991-05-31 1992-12-30 Ici Plc Heterocyclic derivatives
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5519021A (en) 1992-08-07 1996-05-21 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
DE4303657A1 (de) * 1993-02-09 1994-08-11 Bayer Ag Neue Chinolon- und Naphthyridoncarbonsäurederivate
GB9312891D0 (en) 1993-06-22 1993-08-04 Boots Co Plc Therapeutic agents
GB9420168D0 (en) 1994-10-06 1994-11-23 Boots Co Plc Therapeutic agents
GB9420172D0 (en) 1994-10-06 1994-11-23 Boots Co Plc Therapeutic agents
US5801183A (en) 1995-01-27 1998-09-01 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists
US5945431A (en) * 1996-03-15 1999-08-31 Biochem Therapeutics Incorporated Cytomegalovirus inhibiting compounds
AU4172197A (en) 1996-09-10 1998-04-02 Pharmacia & Upjohn Company 8-hydroxy-7-substituted quinolines as anti-viral agents
WO1999010347A1 (en) 1997-08-25 1999-03-04 Neurogen Corporation Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands
US6730682B2 (en) 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
CZ20031028A3 (cs) 2000-10-12 2003-08-13 Merck & Co., Inc. Aza- a polyazanaftalenylkarboxamidy
ATE404537T1 (de) 2002-08-13 2008-08-15 Shionogi & Co Heterocyclische verbindungen mit hiv-integrase- hemmender wirkung

Also Published As

Publication number Publication date
US7279487B2 (en) 2007-10-09
DE60315796D1 (de) 2007-10-04
EP1467970A1 (de) 2004-10-20
CA2472372A1 (en) 2003-07-31
JP2005519907A (ja) 2005-07-07
ES2291642T3 (es) 2008-03-01
CA2472372C (en) 2010-08-17
DE60315796T2 (de) 2008-06-05
EP1467970B1 (de) 2007-08-22
AU2003216049B2 (en) 2008-07-17
JP4523281B2 (ja) 2010-08-11
EP1467970A4 (de) 2005-12-21
US20050119482A1 (en) 2005-06-02
WO2003062204A1 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
ATE370948T1 (de) Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen
NO2020026I1 (no) Raltegravir eller et farmasøytisk akseptabelt salt derav, spesielt kaliumsaltet
ATE355064T1 (de) Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
WO2005086700A3 (en) Hiv integrase inhibitors
ATE364385T1 (de) Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer
ATE345129T1 (de) Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer
WO2004024078A3 (en) Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors
WO2005120516A3 (en) Hiv integrase inhibitors
ATE409187T1 (de) N-(substituierte benzyl)-8-hydroxy-1,6- naphthyridin-7- carbonsäureamide als hiv- integrase-hemmer
DE60322919D1 (de) 8-hydroxy-1-oxotetrahydropyrrolopyrazinverbindungen, die sich als inhibitoren von hiv-integrase eignen
TW200640460A (en) HIV integrase inhibitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties